The Confidence Problem Across Functional Disorders: When a Diagnosis Becomes an Explanation
Functional Neurological Disorder (FND) is hardly alone in having a complicated relationship with diagnostic certainty. Across several medical specialties, clinicians are encouraged to recognise characteristic patterns, make positive diagnoses and avoid unnecessary investigations. There is nothing inherently wrong with this approach. Patients need answers, treatment and clinicians willing to make decisions. The problem begins when confidence in recognising a clinical presentation becomes certainty about what caused it, or when a diagnostic label is treated as though it explains more than the evidence establishes.
This concern extends beyond neurology. Irritable bowel syndrome (IBS), fibromyalgia and other conditions discussed in the literature on functional somatic syndromes have histories of disputed diagnostic criteria, uncertain mechanisms, overlapping presentations and questions about diagnostic accuracy. Researchers within these specialties have openly examined those limitations. Their criticisms do not establish that the diagnoses are invalid, nor do they imply that patients are somehow less genuinely ill. They demonstrate that clinical classifications have boundaries, and that those boundaries matter when clinicians explain diagnoses, make treatment decisions and determine whether further investigation is warranted.
The Limits of a Positive Diagnosis
Modern FND literature strongly advocates diagnosis based on positive clinical evidence rather than simply excluding other neurological conditions. In their 2021 practical review, Bennett and colleagues emphasise examination findings, including patterns of internal inconsistency, while acknowledging diagnostic pitfalls and the possibility of coexisting neurological disease. They caution against diagnosing FND merely because symptoms are unusual, investigations are normal or a patient has psychological difficulties. Their discussion illustrates an important distinction: positive clinical findings may support a diagnosis without establishing every aspect of the patient's underlying illness. The concern arises when confidence in those findings is communicated without equivalent attention to their limitations.
Gastroenterology has adopted a similar emphasis on positive diagnosis. The American College of Gastroenterology's 2021 IBS guideline recommends a positive diagnostic strategy rather than relying entirely on exclusion, while also recommending targeted testing for conditions such as coeliac disease and inflammatory bowel disease in appropriate patients. This approach recognises that identifying a characteristic symptom pattern and considering alternative disease are not mutually exclusive. Yet the limitations of symptom-based criteria have been directly examined. In a systematic review of 25 diagnostic studies, Jellema and colleagues concluded that IBS symptom criteria alone could not accurately exclude organic disease. They did not argue that every patient required exhaustive testing, but demonstrated why diagnostic criteria should not be mistaken for comprehensive exclusion of competing explanations.
Fibromyalgia offers another revealing comparison. In a 2019 study involving 497 rheumatology patients, Wolfe and colleagues found only fair agreement beyond chance between clinician diagnoses and published fibromyalgia criteria, reporting a Cohen's kappa of 0.41. Some patients met the criteria without receiving the diagnosis, while others were diagnosed despite not meeting them. The authors raised concerns about diagnostic validity and clinician bias. This does not establish that fibromyalgia is invalid, nor does it mean the published criteria constitute an infallible reference standard. It demonstrates that even established diagnostic frameworks can be applied inconsistently. The 2016 revision of the fibromyalgia criteria also explicitly recognises that a fibromyalgia diagnosis does not exclude other clinically important illnesses, an acknowledgement that should remain central to clinical reasoning.
The wider debate is longstanding. In their 1999 Lancet review, Wessely, Nimnuan and Sharpe questioned whether several functional somatic syndromes were sufficiently distinct to justify their conventional separation, highlighting substantial overlap between clinical presentations. Their proposed interpretation is itself debatable: shared symptoms do not necessarily establish shared causes, and combining diagnostic categories can introduce additional assumptions. Nevertheless, the paper illustrates that researchers have questioned the boundaries and explanatory value of functional classifications for decades. A clinical label may be useful for organising care without necessarily identifying one underlying mechanism shared by everyone who receives it.
When Diagnostic Confidence Becomes Dangerous
Confidence is not inherently a clinical failing. Medicine cannot operate if every decision is postponed until uncertainty disappears, and many diagnoses across medicine are made without complete knowledge of their causes. The problem is disproportionate confidence: presenting a conclusion as more certain, comprehensive or explanatory than the evidence warrants. A clinician may have sufficient grounds to identify a recognised syndrome and recommend treatment while still acknowledging that its mechanisms are incompletely understood, that diagnostic criteria have limitations and that coexisting disease remains possible. These qualifications do not undermine responsible clinical practice. They define its boundaries.
The danger becomes more serious when a diagnosis discourages reconsideration. Premature diagnostic closure occurs when clinicians settle on an explanation before adequately considering relevant alternatives, while diagnostic overshadowing can occur when new symptoms are attributed to an existing diagnosis without sufficient independent assessment. These are recognised problems in clinical reasoning and are not exclusive to functional disorders. However, where diagnostic categories are heterogeneous and lack definitive biological markers, the need to distinguish observed clinical findings from assumptions about causation becomes especially important. A patient whose symptoms progress, change substantially or develop new objective features may require reassessment, regardless of how confidently the original diagnosis was made.
There is also an ethical obligation to communicate uncertainty accurately. Telling patients that their symptoms meet recognised diagnostic criteria is not equivalent to claiming that the underlying cause has been established. Explaining that investigations have not identified a particular disease is different from asserting that all relevant alternatives have been eliminated. Likewise, describing a proposed mechanism as plausible is not the same as presenting it as demonstrated fact. Patients make decisions about treatment, further investigation and their own health based on these explanations. When important qualifications disappear from the conversation, informed decision-making suffers.
None of the studies discussed here establishes that clinicians across functional specialties routinely conceal uncertainty or deliberately mislead patients. The research documents limitations in diagnostic criteria, classification and clinical assessment; it does not directly measure the honesty of individual consultations. Nevertheless, these limitations create an obligation to avoid overstating what a diagnosis establishes. Scientific uncertainty cannot reasonably be acknowledged in published research and then treated as irrelevant when explaining the same condition to a patient.
The Same Standard for Every Specialty
FND Nope has concentrated much of its scrutiny on Functional Neurological Disorder, but the underlying concern is not confined to neurology. Gastroenterologists, rheumatologists and clinicians working with other functional disorders should face the same questions. What evidence supports the diagnosis? How reliable are the criteria in the population being assessed? Which mechanisms are established and which remain hypothetical? What alternative or coexisting conditions deserve consideration? Under what circumstances should the diagnosis be reconsidered? These are not unreasonable demands or attempts to discredit particular disorders. They are ordinary requirements of scientific accountability.
The literature demonstrates that researchers in several specialties have been willing to question the accuracy, boundaries and explanatory limitations of their own diagnostic frameworks. That willingness should be reflected in clinical communication. Patients do not need clinicians who refuse to make decisions, but they do need clinicians who understand the difference between a supported diagnosis and an exhaustive explanation. Confidence should be proportionate to the evidence, and a diagnosis should remain open to revision when new information warrants it.
Functional diagnoses do not need to be invalid for excessive certainty to cause harm. IBS can be a useful diagnosis without excluding every gastrointestinal disease. Fibromyalgia can describe a recognised clinical syndrome without accounting for every possible cause of pain. FND can be supported by characteristic examination findings without establishing every aspect of a patient's illness. In each case, the diagnosis should help organise clinical understanding rather than replace further reasoning. Medicine owes patients more than a confident label: it owes them an accurate account of what is known, what remains uncertain and what evidence might change the conclusion. Scientific honesty is not the opposite of diagnostic confidence. It is what makes that confidence worthy of trust.
References
- Bennett K et al. (2021). A practical review of functional neurological disorder (FND) for the general physician. Clinical Medicine.
- Lacy BE et al. (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology.
- Jellema P et al. (2009). Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Alimentary Pharmacology & Therapeutics.
- Wolfe F et al. (2019). Diagnosis of Fibromyalgia: Disagreement Between Fibromyalgia Criteria and Clinician-Based Fibromyalgia Diagnosis in a University Clinic. Arthritis Care & Research.
- Wolfe F et al. (2016). 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism.
- Wessely S, Nimnuan C, Sharpe M. (1999). Functional somatic syndromes: one or many? The Lancet.